Here is how Butterfly Network, Inc. (BFLY) and Biora Therapeutics, Inc. (BIOR) have performed compared to their sector so far this year.
After losing some value lately, a hammer chart pattern has been formed for Biora Therapeutics, Inc. (BIOR), indicating that the stock has found support. This, combined with an upward trend in earnings...
Biora Therapeutics, Inc. (BIOR) delivered earnings and revenue surprises of -33.33% and 20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 7.53% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
All Devices Successfully Detected Colon Entry in Patients with Active Ulcerative Colitis...
SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today...
SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today...
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today...
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Biora Therapeutics (BIOR – Research Report) today and set a price target of $6.00. The company's shares closed last Thursday at $0.71,...
Demonstrates OBDS Device Performance and Bioavailability in Animal Models...